# Michael S. Gordon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-s-gordon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,331 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 73 |
| i10-index | 235 |
| Last Known Institution | Friends Research Institute |
| OpenAlex ID | https://openalex.org/A5069690249 |
| ORCID iD | https://orcid.org/0000-0002-7679-9504 |
| Works | 570 |

## Researcher papers

- [Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial](https://scholariq.org/papers/safety-pharmacokinetic-pharmacodynamic-and-efficacy-data-for-the-oral-mek/)
- [Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial](https://scholariq.org/papers/activity-of-the-oral-mek-inhibitor-trametinib-in-patients-with-advanced-melanoma/)
- [A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.](https://scholariq.org/papers/a-randomized-placebo-controlled-trial-of-recombinant-human-interleukin-11-in/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Researcher university

- [Friends Research Institute](https://scholariq.org/institutions/friends-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.